Related Experiment Video
Updated: Jun 29, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer
Francesca Matilde Schipilliti1, Denise Drittone1, Federica Mazzuca2
1Oncological Department, Sant'Andrea Hospital, University Sapienza in Rome, Rome, Italy.
Abstract:
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.
Insights
Triple negative breast cancer (TNBC) treatment is improving with antibody-drug conjugates (ADCs). The novel ADC Dato-DXd shows promise for TNBC, with ongoing trials evaluating its efficacy and safety.
Area of Science:
- Oncology
- Pharmacology
Background:
- Triple negative breast cancer (TNBC) has a poor prognosis due to limited treatment options.
- Antibody-drug conjugates (ADCs) are revolutionizing breast cancer therapy.
- Sacituzumab Govitecan, an anti-TROP2 ADC, is approved for previously treated metastatic TNBC.
Purpose of the Study:
- To review the mechanism of action and pharmacologic activity of the TROP-2 directed ADC, Dato-DXd.
- To summarize the initial efficacy and safety findings of Dato-DXd in TNBC.
- To outline ongoing clinical trials for Dato-DXd in TNBC.
Main Methods:
- Literature review of available data on Dato-DXd.
- Analysis of early clinical trial results for efficacy and safety.
- Compilation of characteristics, inclusion criteria, and endpoints of ongoing trials.
Main Results:
- Dato-DXd demonstrates encouraging results in TNBC treatment.
- Initial data suggest a favorable efficacy and safety profile for Dato-DXd.
- Ongoing trials are actively investigating Dato-DXd's potential in TNBC.
Conclusions:
- Dato-DXd represents a promising novel ADC for TNBC treatment.
- Further clinical evaluation is warranted to establish Dato-DXd's role in TNBC therapy.
More Related Videos
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
